Basic Information
| LncRNA/CircRNA Name | LINCRNA-p21 |
| Synonyms | TP53COR1, TRP53COR1, linc-p21, lincRNA-p21 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | enzalutamide | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qRT-PCR , Western blot , RIP , Luciferase reporter assay , in vitro knockdown etc. |
| Sample | cell lines?(NCI-H660 (CRL-5813), DU145 (HTB-81), PC-3 (CRL-1435), LNCaP (CRL-1740), 293 (CRL-1573) and CWR22RV1 (CRL-2505)) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA-p21 is highly expressed in the NEPC patients derived xenograft tissues (NEPC-PDX).lncRNA-p21 expression is up-regulated in NEPC and Enz treatment could increase the lncRNA-p21 to induce the NED.Enz could promote the lncRNA-p21 transcription via altering the androgen receptor (AR) binding to different androgen-response-elements, which switch the EZH2 function from histone-methyltransferase to non-histone methyltransferase, consequently methylating the STAT3 to promote the NED.EZH2 inhibitor could block the Enz-induced NED. |
| Pubmed ID | 31189930 |
| Year | 2019 |
| Title | LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling |
External Links
| Links for LINCRNA-p21 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |